Neuropathy clinical trials at UCSF
5 in progress, 2 open to eligible people
Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
open to eligible people ages 18 years and up
The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months.
San Francisco 5391959, California 5332921 and other locations
Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program
open to all eligible people
The primary objective of this study is to assess the long-term safety, including pregnancy, infant, and lactation outcomes, of patients with LC-FAOD who are enrolled in the DMP.
San Francisco 5391959, California 5332921 and other locations
Laryngopharyngeal Sensation: Cancer Survivor Cohort
Sorry, not yet accepting patients
A previous study completed in 2022 (NCT05158179) was conducted using cohorts of healthy controls, and adults with general laryngopharyngeal disorders. This study will expand on the previous research to include a separate cohort of adults being seen in clinic for an existing laryngopharyngeal disorder resulting from previous radiation or other cancer treatments.
San Francisco 5391959, California 5332921
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients with Stage II-III Colorectal Cancer
Sorry, in progress, not accepting new patients
This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.
San Francisco 5391959, California 5332921 and other locations
Longitudinal Study in Adults With Multifocal Motor Neuropathy
Sorry, in progress, not accepting new patients
This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect data on their clinical outcomes, quality of life, and use of health care resources. Participants will follow their regular visit schedule with their treating physician, except for an optional second visit occurring 7 to 14 days after the start of the study to collect biomarker data. No IMP will be administered.
San Francisco 5391959, California 5332921 and other locations
Our lead scientists for Neuropathy research studies include Yue Ma, MD.
Last updated: